ArticleThe Journal of investigative dermatology2015
KIT in melanoma: many shades of gray.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review.Melanoma research · 2020Pooled it
- The Role of Tyrosine Kinase in Beauty and Skincare: A Comprehensive Review.Journal of cosmetic dermatology · 2025Review
- Review
- Review
- Integrated transcriptomic and immunological profiling reveals new diagnostic and prognostic models for cutaneous melanoma.Frontiers in pharmacology · 2024Article
- Mastocytosis and Skin Cancer: The Current State of Knowledge.International journal of molecular sciences · 2023Review
- Review
- Autocrine/Paracrine Loop Between SCFFrontiers in immunology · 2022Article
- Epidemiology of brain metastases and leptomeningeal disease.Neuro-oncology · 2021Review
- The Mechanisms for the Association of Cancer and Esophageal Dysmotility Disorders.Medical sciences (Basel, Switzerland) · 2021Review
- The dark side of daylight: photoaging and the tumor microenvironment in melanoma progression.The Journal of clinical investigation · 2021Review
- The tumor genetics of acral melanoma: What should a dermatologist know?JAAD international · 2020Article
- Overcoming Immune Evasion in Melanoma.International journal of molecular sciences · 2020Review
- Current Molecular Markers of Melanoma and Treatment Targets.International journal of molecular sciences · 2020Review
- Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations.Oncotarget · 2019Article
- Automated phosphopeptide enrichment from minute quantities of frozen malignant melanoma tissue.PloS one · 2018Article
- Identification of a gene signature for discriminating metastatic from primary melanoma using a molecular interaction network approach.Scientific reports · 2017Article
- Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA.F1000Research · 2017Article
- Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.Current oncology reports · 2016Review
- Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.Oncotarget · 2015Review
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Activating mutations in KIT have been identified in melanomas of acral and mucosal types and in those arising in chronically sun-damaged skin. Until now, KIT has been considered an oncogenic driver and a potential therapeutic target. However, data presented by Dhal et al. show that in cutaneous melanomas the KIT promoter is a target for hypermethylation, leading to its downregulation. Their observations suggest that signaling pathways downstream of KIT may have distinct and opposing roles in the pathogenesis of melanoma subtypes. This will have important implications for the use of KIT inhibitors in treating melanomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.